公司資料
AnaptysBio, Inc. 股價、新聞與催化劑
- 股票代碼:
- ANAB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
59.69 USD (+2.09%)
收盤價
最後更新: 2026年8月17日
1.49B USD
市值
股價為何變動
As of Aug 17, 2026, ANAB closed up 2.09% at $59.69. No new same-company headline was identified in the current news window.
公司概覽
Biopharma Royalty Company
Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.
Jemperli Economics
Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers.
Imsidolimab Economics
The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.
未來催化劑
- Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
- Data from the Phase 2 AZUR-4 colon cancer study are expected in the fourth quarter of 2026.
- The FDA PDUFA action date for imsidolimab in generalized pustular psoriasis is December 12, 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。